GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2
GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2
Contenu indisponible. Consultez la source originale.
GSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.